Late toxicity is not increased in BRCA1/BRCA2 mutation carriers undergoing breast radiotherapy in the United Kingdom

Clinical Cancer Research

Volumn 12, Issue 23, 2006, Pages 7025-7032

  Shanley, Susan ^a,e,n   McReynolds, Kate ^a,f   Ardern Jones, Audrey ^a   Ahern, Roger ^a   Fernando, Indrajit ^g   Yarnold, John ^a   Evans, Gareth ^h   Eccles, Diana ^j   Hodgson, Shirley ^b,c   Ashley, Sue ^a   Ashcroft, Linda ⁱ   Tutt, Andrew ^b   Bancroft, Elizabeth ^a   Short, Susan ^d   Gui, Gerald ^a   Barr, Lester ⁱ   Baildam, Andrew ⁱ   Howell, Anthony ⁱ   Royle, Gavin ^k   Pierce, Lori ^l   Easton, Douglas ^m   Eeles, Rosalind ^a   more..

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^c ST GEORGE S HOSPITAL   (United Kingdom)

^d Gray Cancer Institute   (United Kingdom)

^e WESTMEAD HOSPITAL   (Australia)

^f VANDERBILT UNIVERSITY   (United States)

^g UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^h ST MARY S HOSPITAL   (United States)

ⁱ CHRISTIE HOSPITAL   (United Kingdom)

^j PRINCESS ANNE HOSPITAL   (United Kingdom)

^k ROYAL SOUTH HANTS HOSPITAL   (United Kingdom)

^l UNIVERSITY OF MICHIGAN   (United States)

^m UNIVERSITY OF CAMBRIDGE   (United Kingdom)

ⁿ INSTITUTE OF CANCER RESEARCH   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BRCA1 PROTEIN; BRCA2 PROTEIN; TAMOXIFEN;

ADULT; AGED; ARTICLE; BONE NECROSIS; BREAST CANCER; CANCER CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE MUTATION; HETEROZYGOTE DETECTION; HORMONE SUBSTITUTION; HUMAN; HUMAN TISSUE; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MEDICAL ASSESSMENT; PERICARDITIS; PRIORITY JOURNAL; RADIATION EXPOSURE; RIB FRACTURE; SOFT TISSUE DISEASE; TELANGIECTASIA; UNITED KINGDOM;

ADULT; AGED; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; GENES, BRCA1; GENES, BRCA2; GERM-LINE MUTATION; GREAT BRITAIN; HETEROZYGOTE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; RADIOTHERAPY; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33845792038     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-1244     Document Type: Article

References (9)

1. Chabner E, Nixon A, Gelman R, et al. Family history and treatment outcome in young women after breast-conserving surgery and radiation therapy for early stage breast cancer. J Clin Oncol 1998;16:2045-51.
2. Harris EER, Schultz DJS, Peters CA, Solin LJ. Relationship of family history and outcome after breast conservation therapy in women with ductal carcinoma in situ of the breast. Int J Radiat Oncol Biol Phys 2000;48:933-42.
3. Gaffney DK, Brohet RM, Lewis CM, et al. Response to radiation therapy and prognosis in breast cancer patients with BRCA1 and BRCA2 mutations. Radiother Oncol 1998;47:129-36.
4. Pierce LJ, Strawderman M, Narod SA, et al. Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations. J Clin Oncol 2000;18:3360-9.
5. Pavy JJ, Denekamp J, Letschert J, et al. Late effects toxicity scoring: the SOMA scale. Radiother Oncol 1995;35:11-5.
6. Perneger T. What's wrong with Bonferroni adjustments. BMJ 1998;316:1236-8.
7. Hoeller U, Tribius S, Kuhlmey A, Grader K, Fehlauer F, Alberti W. Increasing the rate of late toxicity by changing the score? A comparison of the RTOG/EORTC and LENT/SOMA scores. Int J Radiat Oncol Biol Phys 2003;55:1013-8.
8. Fehlauer F, Tribius S, Holler U, et al. Long-term radiation sequelae after breast-conserving therapy in women with early stage breast cancer: an observational study using the LENT-SOMA scoring system. Int J Radiat Oncol Biol Phys 2003;55:651-8.
9. Vrieling C, Collette L, Fourquet A, et al. The influence of the boost in breast conserving therapy on cosmetic outcome in the EORTC "Boost versus No Boost" Trial. Int J Radiat Oncol Biol Phys 1999;45:677-85.